A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Bristol-Myers Squibb
Amgen
NuCana plc
Akeso
OncoC4, Inc.
GlaxoSmithKline
Medical University of Vienna
OncoResponse, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University of Alabama at Birmingham
European Organisation for Research and Treatment of Cancer - EORTC
Seagen Inc.
University of Jena
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of Vermont
University College, London
Sanofi
Dana-Farber Cancer Institute